Colorectal Cancer Articles | Page 2

Expert Discusses Treatment Options in Advanced CRC
Cathy Eng, MD, discusses optimizing sequencing beyond disease progression in CRC.
Refining Chemo Regimens Among Keys to CRC Advances
Hans-Joachim Schmoll, MD, discusses updated CHARTA findings, the current role of chemotherapy in patients with metastatic colorectal cancer (CRC), and his predictions for the future CRC treatment landscape.
Bevacizumab Biosimilar Nears European Approval
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of the bevacizumab biosimilar ABP 215 for the treatment of patients across several tumor types.
MSI-H Experience Delivers Another Exciting Breakthrough in Immuno-Oncology
Immunotherapy is being positioned as an earlier therapeutic option for patients with high levels of microsatellite instability or mismatch repair deficiency, regardless of their tumor location, expert says. 
CDK4/6 Inhibitors Explored in KRAS-Mutant Cancers
A new generation of more selective inhibitors of CDK4 and CDK6 has entered the clinic in combination therapies for patients with breast cancer. These agents also are being investigated in patients with KRAS-mutant malignancies.
Tanios Bekaii-Saab, MD, discusses the emerging role of immunotherapy in patients with MSI-H colorectal cancer. 
Grothey Highlights Biomarker Research in CRC
Axel Grothey, MD, discusses current first-line treatments for patients with CRC and the importance of developing biomarkers for this population.
Therapies in Development to Improve Outcomes in BRAF-Mutated CRC
Tim G. Larson, MD, discusses emerging data involving immunotherapy for patients with microsatellite instability (MSI)/microsatellite stable (MSS) colorectal cancer (CRC) and highlighted some of the identified molecular mutations in patients with CRC
Expert Reflects on Recent Trial Results in CRC and Small Bowel Cancer
Heinz-Josef Lenz, MD, discusses his study of molecular variations between small bowel adenocarcinomas, right-sided colon cancers, and gastroesophageal cancers.
FDA Approves First Biosimilar for Cancer Treatment
The FDA approved the first biosimilar for the treatment of cancer. ABP-215 (bevacizumab-awwb; Mvasi), a biosimilar for bevacizumab (Avastin), is indicated for the treatment of colorectal, lung, brain, kidney, and cervical cancers in adult patients.
Publication Bottom Border
Border Publication